Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Friday, March 31, 2023.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2023 (2023-03-31): 25.74%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
43.05%
RETURN ON EQUITY (ROE) AVG 3Y
79.24%
RETURN ON EQUITY (ROE) AVG 5Y
79.24%
RETURN ON EQUITY (ROE) AVG 10Y
-82.50%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Ironwood Pharmaceuticals, Inc.
Market Cap
$597.55M
Return on Equity (ROE)
N/A
TTM Avg
43.05%
3Y Avg
79.24%
5Y Avg
79.24%
Market Cap
$596.01M
Return on Equity (ROE)
-21.51%
TTM Avg
-20.05%
3Y Avg
-35.91%
5Y Avg
-26.18%
Market Cap
$584.48M
Return on Equity (ROE)
-8.42%
TTM Avg
-4.61%
3Y Avg
-3.17%
5Y Avg
11.46%
Market Cap
$611.57M
Return on Equity (ROE)
-24.06%
TTM Avg
-36.09%
3Y Avg
-34.99%
5Y Avg
-44.03%
Market Cap
$583.31M
Return on Equity (ROE)
-11.56%
TTM Avg
-11.05%
3Y Avg
-6.83%
5Y Avg
-8.10%
Market Cap
$578.40M
Return on Equity (ROE)
N/A
TTM Avg
161.13%
3Y Avg
93.89%
5Y Avg
96.07%
Market Cap
$619.15M
Return on Equity (ROE)
-97.31%
TTM Avg
-116.17%
3Y Avg
-82.05%
5Y Avg
-65.68%
Market Cap
$571.13M
Return on Equity (ROE)
40.62%
TTM Avg
9.52%
3Y Avg
-25.24%
5Y Avg
-32.61%
Market Cap
$630.63M
Return on Equity (ROE)
-17.01%
TTM Avg
-22.91%
3Y Avg
-17.12%
5Y Avg
-14.58%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ironwood Pharmaceuticals, Inc. (IRWD) | $597.55M | N/A | 43.05% | 79.24% | 79.24% |
| AngioDynamics, Inc. (ANGO)vs › | $596.01M | -21.51% | -20.05% | -35.91% | -26.18% |
| Fulgent Genetics, Inc. (FLGT)vs › | $584.48M | -8.42% | -4.61% | -3.17% | 11.46% |
| Climb Bio, Inc. (CLYM)vs › | $611.57M | -24.06% | -36.09% | -34.99% | -44.03% |
| OrthoPediatrics Corp. (KIDS)vs › | $583.31M | -11.56% | -11.05% | -6.83% | -8.10% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $578.40M | N/A | 161.13% | 93.89% | 96.07% |
| SOPHiA GENETICS S.A. (SOPH)vs › | $619.15M | -97.31% | -116.17% | -82.05% | -65.68% |
| CorMedix Inc. (CRMD)vs › | $571.13M | 40.62% | 9.52% | -25.24% | -32.61% |
| OmniAb, Inc. (OABI)vs › | $630.63M | -17.01% | -22.91% | -17.12% | -14.58% |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | -471.98% | -147.16% | -120.43% | -93.49% |
ROE
N/A
ROA
45.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2023-03-31 | 25.74% |
| 2022-12-31 | 26.83% |
| 2022-09-30 | 28.35% |
| 2022-06-30 | 32.48% |
| 2022-03-31 | 101.84% |
| 2021-12-31 | 87.22% |
| 2021-09-30 | 91.44% |
| 2021-06-30 | 99.43% |
| 2021-03-31 | 129.55% |
| 2020-12-31 | 169.50% |
| 2017-03-31 | -407.98% |
| 2016-12-31 | -122.47% |
| 2016-09-30 | -138.32% |
| 2016-06-30 | -118.49% |
| 2016-03-31 | -134.98% |
| 2015-12-31 | -149.98% |
| 2015-09-30 | -165.52% |
| 2015-06-30 | -114.68% |
| 2015-03-31 | -254.12% |
| 2014-12-31 | -214.13% |
| 2014-09-30 | -188.59% |
| 2014-06-30 | -157.75% |
| 2014-03-31 | -120.95% |
| 2013-12-31 | -713.70% |
| 2013-09-30 | -314.31% |
| 2013-06-30 | -111.37% |
| 2013-03-31 | -223.72% |
| 2012-12-31 | -50.42% |
| 2012-09-30 | -19.63% |
| 2012-06-30 | -80.77% |
| 2012-03-31 | -49.99% |
| 2011-12-31 | -59.03% |
| 2011-09-30 | -61.57% |
| 2011-06-30 | -43.93% |
| 2011-03-31 | -38.36% |
| 2010-12-31 | -33.21% |
| 2010-09-30 | -38.82% |
| 2010-06-30 | -39.76% |
| 2010-03-31 | -36.62% |
| 2009-09-30 | -302.22% |
